Acute effects of blood flow restriction-augmented passive manual therapy on hip flexion range of motion (Straight Leg Raise) and muscle stiffness: A within-subject controlled trial

Acute effects of blood flow restriction-augmented passive manual therapy on hip flexion range of motion (Straight Leg Raise) and muscle stiffness: A within-subject controlled trial - BFR-SLR Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000061381

Enrollment

Registered

2026-04-27

Start date

2026-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults (musculoskeletal flexibility assessment)

Interventions

BFR condition: A pneumatic cuff (FAST BELT, 28 cm width

Inifia Co., Ltd., Tokyo, Japan) is applied to the proximal thigh and inflated to 200-250 mmHg. Six consecutive passive manual techniques are performed for 20 seconds each, totaling approximately 2 min

(2) passive stretching of the hamstrings and lower leg (supine)

(3) passive stretching of the gluteus medius (supine)

(4) passive stretching of the gluteus maximus (supine)

(5) passive stretching of the hip adductors (supine)

(6) passive stretching of the quadriceps (side-lying). All techniques are performed by the clinician to the participant&#39

s tolerable end range. The cuff is deflated immediately after the final technique. Intervention time: approximately 2 minutes per limb. Control condition: The contralateral limb undergoes the same six

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Healthy adults aged 20-65 years; (2) No current lower limb injuries; (3) No contraindications to blood flow restriction (BFR), such as deep vein thrombosis, peripheral vascular disease, or pregnancy; (4) Able to provide written informed consent; (5) Able to undergo passive manual therapy on both lower limbs.

Exclusion criteria

Exclusion criteria: (1) Deep vein thrombosis (DVT) or history thereof; (2) Peripheral vascular disease; (3) Pregnancy; (4) Severe hypertension (systolic >=180 mmHg or diastolic >=110 mmHg); (5) Use of anticoagulant medication; (6) Acute musculoskeletal injury; (7) Other conditions deemed unsafe by the principal investigator.

Design outcomes

Primary

Measure	Time frame
Pre-to-post change in passive hip flexion range of motion (ROM) measured by the Straight Leg Raise (SLR) test. With the participant in the supine position and both lower limbs in extension on the examination table, the examiner passively elevates the test limb while maintaining the knee in full extension, until the participant's tolerable maximum (point of discomfort). Hip flexion angle is measured using a standard goniometer with the axis aligned at the greater trochanter, with the stationary arm parallel to the examination table and the movable arm aligned with the long axis of the femur (greater trochanter to lateral femoral epicondyle). Three measurements are taken at each time point; the mean value is used for analysis. Timing: immediately before and immediately after the intervention.	—

Measure

Time frame

Pre-to-post change in passive hip flexion range of motion (ROM) measured by the Straight Leg Raise (SLR) test. With the participant in the supine position and both lower limbs in extension on the examination table, the examiner passively elevates the test limb while maintaining the knee in full extension, until the participant's tolerable maximum (point of discomfort). Hip flexion angle is measured using a standard goniometer with the axis aligned at the greater trochanter, with the stationary arm parallel to the examination table and the movable arm aligned with the long axis of the femur (greater trochanter to lateral femoral epicondyle). Three measurements are taken at each time point; the mean value is used for analysis. Timing: immediately before and immediately after the intervention.

—

Secondary

Measure	Time frame
1) Pre-to-post change in tissue hardness of the rectus femoris (quadriceps), measured using NEUTONE TDM-N1 (TRY-ALL Corp., Chiba, Japan). The device measures the penetration resistance of a hemispherical indenter at standardized contact pressure, providing relative hardness values on a unitless 0-100 scale. Three measurements per site; the mean value is used for analysis. Timing: immediately before and immediately after the intervention. 2) Pre-to-post change in tissue hardness of the biceps femoris (hamstrings), measured using the same device, method, and timing as above. 3) Adverse events (numbness/subcutaneous bleeding at the cuff application site, pain during the intervention, etc.), evaluated throughout and after the intervention.	—

Measure

Time frame

1) Pre-to-post change in tissue hardness of the rectus femoris (quadriceps), measured using NEUTONE TDM-N1 (TRY-ALL Corp., Chiba, Japan). The device measures the penetration resistance of a hemispherical indenter at standardized contact pressure, providing relative hardness values on a unitless 0-100 scale. Three measurements per site; the mean value is used for analysis. Timing: immediately before and immediately after the intervention. 2) Pre-to-post change in tissue hardness of the biceps femoris (hamstrings), measured using the same device, method, and timing as above. 3) Adverse events (numbness/subcutaneous bleeding at the cuff application site, pain during the intervention, etc.), evaluated throughout and after the intervention.

—

Countries

Japan

Contacts

Public ContactYasuhiro Aki

Givers Holdings Co., Ltd. Headquarters

cocoro.aki@gmail.com09082822314

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026